Agilent Technologies acquired Luxcel Biosciences, a transaction completed in January 2018.
Luxcel Biosciences operates in Life Sciences and Applied Markets, is based in Cork, Ireland. Luxcel Biosciences develops real-time, fluorescence plate-reader-based in vitro cell assay kits for cell metabolism, drug safety and toxicity, hypoxia and oxidative stress, aimed at research and pharmaceutical customers.
Luxcel's plate-reader-compatible assays complemented Agilent's Seahorse XF technology and accelerated its expansion into pharma discovery and in vitro toxicology screening.
Luxcel is highly complementary to our Seahorse offerings.Todd Christian, General Manager, Agilent Cell Analysis Division
Advisory firms were not disclosed for this transaction.